• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Real Estate·DXS.AX
Share

DEXUS Stocks

A$ 5.43Last Updated 01.07.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

A$ 4.26B

A$ 5.43
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Dexus stands as a premier Australian real estate entity, meticulously managing a high-quality, Australian-focused property portfolio valued at $44.3 billion. Our success is fundamentally built upon strong relationships, as we are dedicated to partnering with our customers to create engaging and inspiring environments. Our investment focus is solely on Australia, where we directly own $16.5 billion in office and industrial assets. Beyond this, we expertly manage an additional $15.6 billion in diverse properties—including office, retail, industrial, and healthcare—for various third-party clients. A substantial $11.4 billion development pipeline is set to fuel the growth of both our owned and managed portfolios, enhancing future financial returns. As Australia's preferred office partner, we provide 1.6 million square meters of workspace across 51 properties. Dexus (ASX: DXS) is a Top 50 company by market capitalization on the Australian Securities Exchange, backed by a global base of over 29,000 investors spanning 24 countries. With 36 years of profound expertise in property investment, development, and asset management, we demonstrate a proven history of excellence in capital and risk stewardship, ensuring outstanding service for tenants and delivering superior risk-adjusted returns for our investors.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, 'expensive' on EV/

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of DXS.AX is 6.8 and suggests 23.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.07.2026 20:33

"A Key Source of Value and Risk": Wall Street's Top Tech Optimist Assesses SpaceX

01.07.2026 19:21

Companies laid off employees because of artificial intelligence. Some came to regret it.

01.07.2026 18:59

Meta will launch a cloud infrastructure business. It will compete with Google and Nebius

01.07.2026 18:47

BlackRock is betting on scarce resources in AI supply chains. How should you build your portfolio?

01.07.2026 18:39

Shares of pharmaceutical company Galderma plummeted: The U.S. has halted sales of a Botox generic

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026